Boston Scientific Receives FDA Clearance for Express Biliary SD Stent System

Strategic Insights -

Boston Scientific Corporation, a worldwide developer and manufacturer of medical devices, has announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Express(R) Biliary SD Monorail(R) Premounted Stent System for the treatment of malignant biliary tumors. This innovative stent system combines features from two of Boston Scientific's breakthrough technologies, the Express stent and the Maverick(R) balloon catheter, to provide enhanced scaffolding, delivery, and precise placement. The device features "6F" guide catheter compatibility and improved tracking to enhance deliverability, making it a valuable asset for interventional medical specialists.

Key Takeaways:

  • Boston Scientific has received 510(k) clearance from the FDA to market its Express Biliary SD Stent System for the treatment of malignant biliary tumors.
  • The stent system combines features from the Express stent and the Maverick balloon catheter to provide increased scaffolding, delivery, and precise placement.
  • The device features "6F" guide catheter compatibility and improved tracking to enhance deliverability.
  • Minimal stent shortening and customized balloon lengths for each stent length are designed to enable accurate placement.
  • The increased stent scaffolding at the proximal end provides lumen support.
  • The stent system is expected to be launched in the U.S. immediately, with a promising future in interventional medical specialties.
  • Boston Scientific's President of Peripheral Interventions business, Matthew Jenusaitis, emphasized the exceptional trackability and deliverability of the stent system without compromising stent radial strength.

Statistics:

  • 510(k) clearance from the FDA was received by Boston Scientific for the Express Biliary SD Stent System.
  • The stent system combines two proprietary technologies from Boston Scientific.
  • "6F" guide catheter compatibility is featured in the new device.
  • Increased scaffolding at the proximal end of the stent provides lumen support.
  • Minimal stent shortening is designed to enable accurate placement.

Sources:

  • Boston Scientific Corporation press release.
  • Securities and Exchange Commission filings.